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1. Introduction 
Epidermolysis bullosa (EB) is a very heterogeneous hereditary disease of the skin and 
mucous membranes, characterized by erosions and blistering after minor traumatization. 
Up to now at least 12 genes are known to underlie EB, which render structural and 
mechanical stability of the skin (Fine et al., 2008). The characteristic blister formation occurs 
on the level of the basement membrane zone and the basal keratinocytes, depending on the 
gene, which is mutated. In EB simplex (EBS) the split formation in the skin occurs due to 
cytolysis of the basal keratinocytes, in junctional EB (JEB) within the lamina lucida and in 
dystrophic EB (DEB) on the dermal aspect of the basement membrane zone. Due to the 
clinical and genetic heterogeneity of this disease the development of a gene therapy is 
challenging, since every type of EB has to be targeted separately. Furthermore, the different 
subtypes differ in their mode of inheritance. Especially for basal EB simplex, where 
mutations in the keratin 5 (K5), keratin 14 (K14) and plectin (PLEC) genes may cause the 
clinical phenotype, dominant mutations are frequent. But also in dystrophic EB, where 
mutations in the collagen VII gene (COL7A1) are causative for the disease, dominantly 
inherited subtypes are known. Another characteristic feature of the involved genes is that 
many of them are very large and exceed the packaging capacities of commonly used (viral) 
vectors (e.g. COL7A1: ~9,3kb, PLEC: ~14.8kb). Functionally, all genes involved in EB have 
structural significance. Whereas keratin 5 and keratin 14 are major components of the 
cytoskeleton in basal keratinocytes, plectin is a cytolinker protein, connecting the actin 
filament network with the microtubules, the intermediate filaments and the 
hemidesmosomes and desmosomes. Isoforms of plectin are expressed in many cell types 
and always have “networking” functions. This is the reason why epidermolysis bullosa 
triggered by mutations in this gene goes along with muscular dystrophy and pyloric atresia. 
12 plectin isoforms, differing in their 5’ transcript portion have been identified up to now, 
most of them differing in their first exon. However, the structure and mode of function is 
comparable between all isoforms (Rezniczek et al., 2003). Structurally, plectin consists of two 
globular domains, flanking a central rod domain. The 5’ globular domain is encoded by 
exons 1 to 30 and is over 4kb in length, whereas the rod is encoded by one single 3.38kb 
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exon. Plectin peptides form homodimers with a central coiled-coil of alpha helices and two 
globular domains. Within the globular domains the binding sites for its various binding 
partners are situated. Therefore, mutations in the rod cause mainly EBS with muscular 
dystrophy, whereas EBS with pylorus atresia is caused by mutations outside exon 31 
(Natsuga et al., 2010). In this chapter we describe a trans-splicing based gene therapeutic 
approach on the example of epidermolysis bullosa simplex, caused by mutations in the 
PLEC gene. Based on the first proof-of-principle publication from 2008 we developed a 
screening method to correct patient fibroblasts with a high efficiency and specificity, 
rendering this approach a potential candidate for future in vivo studies.  
2. Gene therapy in EB 
For many devastating diseases gene therapy is the only hope for a curative intervention. 
Many efforts have been made in a spectrum of gene therapeutic strategies, resulting in a 
small range of gene therapeutic approaches available in vitro, each having its advantages 
and limitations.  
A very straight-forward approach is gene supplementation therapy, in which a wildtype 
cDNA copy of a given mutated gene is brought into a cell to revert the phenotype. This gene 
complementation approach results in the rescue of the phenotype by providing the 
functional protein. Full-length cDNA therapy can be used for most recessively inherited 
diseases, where the transgene does not exceed the size of the packaging capacity of the 
vector of choice. In EB, cDNA therapy was already used for collagen 17 (COL17A1), laminin 
beta 3 (LAMB3) (Dellambra et al., 2000; Dellambra et al., 1998), integrin beta 4 (ITGB4) 
(Dellambra et al., 2001) and collagen 7 (COL7A1) (Siprashvili et al., 2010). In 2006, De Luca 
and his group applied ex vivo gene therapy for a patient suffering from recessive dystrophic 
EB for the first time (Mavilio et al., 2006). Patient’s epidermal stem cells were transduced 
with a LAMB3 expressing retrovirus. Expanded skin sheets were transplanted onto the 
anterior parts of the patient’s legs, showing complete epidermal regeneration after eight 
weeks. Molecular analysis confirmed the correct integration of the LAMB3 chain in the 
laminin-332 protein, rendering integrity to the transplanted skin section. 
Even though great achievements were made also for other genes, cDNA therapy has 
limitations. In the case of the LAMB3 approach described above, some case specific 
characteristics facilitated the success of this application. These were the autosomal recessive 
mode of inheritance, the limited size of the LAMB3 coding region, the residual 5% gene 
expression of the endogenous LAMB3 alleles (avoiding immune rejection) and the nature of 
LAMB3 in making part in a trimer, thereby avoiding an excess of the functional protein, as 
the amount of available laminin-332 is limited by laminin alpha 3 and laminin gamma 2. 
This last point is crucial as also overexpression of the transgene can have major impact on 
the therapeutic outcome. 
For other genes the starting situation is different. Mutated genes can be very large or 
dominantly inherited, or they need strict expression control due to their negative 
interference when overexpressed. Quite contrary, it was found that low levels of functional 
protein can be sufficient to render a normal phenotype. For this reason cDNA therapy is 
often complemented with knockdown approaches like RNA interference (RNAi) or 
antisense oligonucleotides (ASOs) to knock down the mutated gene and minimizing an 
excess of the transcript.  
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But not only complementary, but also standing alone such alternative strategies were 
developed, many of them acting on RNA level. Therapy on RNA level has the advantage 
that cell targeting does not have to be as strict, since the interfering process can only take 
place in cells actively expressing the targeted gene. This also regulates the amount of 
interference, thus avoiding the overexpression of the respective gene. A widely applied 
approach is the use of interfering RNAs (RNAi). There, specifically designed short-hairpin 
RNAs (shRNAs) or short interfering RNAs (siRNA) are introduced into cells of interest. 
After processing, specific 21bp RNA fragments are incorporated in an RNA induced 
silencing complex (RISC), specifically hybridizing to an allele harbouring a mutation. This 
leads to the cleavage of the target mRNA (Siomi and Siomi, 2009).  
For keratin 14, RNAi was used for characterization studies of EBS (Werner et al., 2004; 
Russell et al., 2009). However, the drawback of RNAi is that even though theoretically any 
gene and any mutation can be targeted, the risk of haploinsufficiency has to be considered. 
To meet this problem, rescue approaches are conducted by introducing the wildtype cDNA, 
leading to the limitations discussed above. 
Another approach on RNA level is the use of ribozymes. Ribozymes are RNA molecules, 
which can specifically cleave themselves, a DNA or RNA molecule at a specific site, 
mediating degradation or ligation of yonder. The mostly used ribozymes are hammerhead 
ribozymes and group-I-intron self-splicing ribozymes. Both have recognition sites 
specifically hybridizing to a target mRNA, mediating cleavage or splicing. Group-I-self 
splicing ribozymes can be altered to introduce a desired cDNA portion to be trans-spliced 
3’ of the endogenous target site. Besides the fact that recognition sites of ribozymes are 
rather short (~ 30nt for group-I-self splicing introns) and therefore increasing the 
probability of hybridizing unspecifically or off-target, only downstream gene portions can 
be replaced. For 5’ mRNA stretches this approach is not applicable. Regarding EB, 
McLean I and Terron A engineered three ribozymes mediating specific cleavage of EBS 
underlying keratin 14 (McLean & Terron, 2002). Cleavage of more than 90% of 
endogenous keratin 14 in cultured keratinocytes was achieved upon transfection. 
However, no differentiation between wildtype and mutated alleles was possible, resulting 
in a nearly complete loss of K14 mRNA, necessitating rescue by ribozyme resistant 
wildtype keratin 14. Given the limitations of the above mentioned approaches we assume 
that Spliceosome Mediated RNA Trans-splicing (SMaRT) is a promising tool for gene 
therapy.  
2.1 Spliceosome Mediated RNA Trans-Splicing 
Spliceosome Mediated RNA Trans-Splicing (SMaRT) is a gene therapeutic approach, taking 
advantage of the cell’s spliceosome to recombine two distinct pre-mRNAs to result in one 
mature mRNA. Pre-mRNA splicing is a naturally occurring process during mRNA 
maturation, which was first seen in trypanosomes, nematodes and recently also in humans 
(Murphy et al., 1986; Flouriot et al., 2002; Davis et al., 1995). During trans-splicing, the 
spliceosome ligates a 5’ exon from one pre-mRNA with a 3’ exon from another pre-mRNA, 
thereby producing an “alternative” mature mRNA, composed of exons derived from two 
different precursors. For SMaRT, this process is utilized to replace a disease causing gene 
portion by its wildtype copy. With this technology, any coding region of interest can be 
trans-spliced to any targeted, endogenous pre-mRNA (Puttaraju et al., 1999). Depending on 
the gene portion to be replaced, 5’ exon replacement, 3’ exon replacement and internal exon 
replacement (IER) are distinct (Figure 1).  
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Commonly, SMaRT is applied as a therapeutic tool, replacing gene portions harbouring a 
disease relevant mutation. Such settings were reported for epidermolysis bullosa (COL7A1, 
KRT14, PLEC) (Murauer et al., 2010; Wally et al., 2010; Wally et al., 2008), Duchenne 
muscular dystrophy (Lorain et al., 2010), cystic fibrosis (Liu et al., 2002; Song et al., 2009), 
frontotemporal dementia with parkinsonism (Rodriguez-Martin et al., 2009), severe 
combined immunodeficiency (Zayed et al., 2007), spinal muscular atrophy (Coady et al., 
2007), sickle cell anemia and ß-thalassemia (Kierlin-Duncan and Sullenger, 2007). First in 
vivo assays showed the functionality of SMaRT in a mouse model of spinal muscular 
atrophy (Coady et al., 2008; Coady and Lorson, 2010). However, SMaRT has also been 
shown to be functional for a number of other approaches like in vivo imaging (Walls et al., 
2008), antibody and therapeutic protein production (Wang et al., 2009; Iwasaki et al., 2009) 
and suicide therapy in squamous cell carcinoma (Gruber et al., 2011).  
 
 
Fig. 1. RNA trans-splicing can be performed to replace one or more (a) 5’, (b) 3’ or (c) 
internal exons.  
Technically, SMaRT is triggered by RNA-trans-splicing molecules (RTMs), which are 
specifically engineered for targeting a selected endogenous mRNA. Depending on the type of 
trans-splicing to be applied (5’, 3’ or IER), RTMs have to comprise certain features facilitating 
the trans-splicing process to take place. These are (a) The coding region to be replaced or 
integrated, (b) a hybridization/binding domain (BD), (c) a spacer region for sterical reasons 
and (d) splicing elements like a branch point (BP), polypyrimidine tract (PPT) and functional 
splice sites (SS). For 5’ trans-splicing the RTM comprises the 5’ (wildtype) coding sequence to 
be replaced, a spacer region and a binding domain. The binding domain hybridizes to the 
targeted intron, facilitating the generation of a mature mRNA mediated by the cell’s 
spliceosome, comprising the 5’ exons from the RTM and the 3’ exons from the endogenous 
target. For 3’ trans-splicing a PPT and a BP have to be included for spliceosome assembly (for 
5’ trans-splicing PPT and BP are provided by the endogenous target intron). Internal exon 
replacement is a combination of 5’ and 3’ trans-splicing (Figure 1). 
Recent studies have shown that the binding domain is crucial for the efficiency, 
functionality and specificity of the replacement process. The binding domain is cloned 
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reverse and complementary and usually targets the intron adjacent to the most central exon 
to be replaced. Recent studies showed that slight variations in the sequence can render an 
RTM from a highly functional to a non-functional or very weak RTM. The mechanisms to 
consider when rationally designing a binding domain are not yet clearly understood.  
3. SMaRT for EBS-MD 
Correction of PLEC by spliceosome mediated RNA trans-splicing was first demonstrated 
2008 (Wally et al., 2008). In brief, a rationally designed RTM was engineered, targeting 
intron 9 to replace the upstream coding sequence including exon 9 of the endogenous PLEC 
mRNA. EBS-MD patient fibroblasts, harbouring a 3bp insertion in exon 9 (1287ins3) (Bauer 
et al., 2001) were transduced with the RTM and trans-splicing was monitored on RNA level, 
protein level and by immunofluorescence microscopy. An increase of full-length plectin 
protein by 58,7% was detected in transfected fibroblasts, whereas untreated fibroblasts 
showed hardly any expression. Even though the whole amount of plectin was still less than 
in wildtype fibroblasts, characteristic cytoplasmatic plectin-specific staining was detected by 
immunofluorescence microscopy. On RNA level, semi-quantitative real-time PCR (SQRT-
PCR) revealed an increase of 83,42% of plectin mRNA expression. The rationally designed 
RTM used in this study was designed to cover the 3’ exon 9/intron 10 junction of the plectin 
pre-mRNA. Even though these results were promising, potential improvement by the 
variation of the binding domain was likely to be achieved. We therefore established a 
method to identify highly efficient binding domains for any gene of interest from a large 
pool of RTMs with randomly generated binding domains. From these libraries highly potent 
RTMs can be isolated and much information about the design of yonder can be obtained. 
4. Principles of a fluorescence based RTM screen 
The studies mentioned above showed that the binding domain is crucial for the efficiency 
and specificity of the trans-splicing process. Even minor variations in binding position, 
length and composition of the BDs result in significantly different efficiencies of the trans-
splicing process. Rational design and evaluation of RTM binding domains can be an 
arduous process as there are no convincing criteria for the design of the binding domain. To 
simplify the process of RTM design we have developed a screening system that can be used 
to select the most efficient RTMs from a library containing a diversity of RTMs with 
complementary binding domains (BDs) for a certain target region of a pre-mRNA of 
interest. Using this method we can test a high number of RTMs for the efficiency of 
randomly generated binding domains. Binding domains are obtained by sonication or 
restriction digest of the targeted exonic and/or intronic region of the gene of interest. The 
resulting fragments have a length between 50 and 400bp (depending on the target region of 
choice) and are cloned into a fluorescence based RTM backbone. This random cloning 
results in the inclusion of one or more binding domains in a sense or antisense orientation, 
thereby resulting in about 50% of RTMs with a binding domain in a correct orientation for 
target hybridization, which is complementary. The vector backbone consists of a 
fluorescence reporter gene (e.g. dsRed) as transfection control and a 5’ or 3’ portion of a 
second fluorescence reporter gene (e.g. acGFP) respectively, mimicking the target gene 
portion to be trans-spliced to, therefore being the trans-splicing reporter. The generated RTM 
libraries are co-transfected with a corresponding target vector, harbouring the targeted full-
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length exonic and/or intronic region and the respective 5’ or 3’ reporter gene portion. 
Crucial is the inclusion of functional splice sites at the junctions of the split fluorescence 
reporter to facilitate trans-splicing. Functional trans-splicing upon co-transfection results in 
cells double positive for both reporter genes. The ratio between the transfection control 
reporter and the trans-splicing reporter gives information about the quality of the RTM. 
Cells transfected by highly functional RTMs show a proportional transfection control 
expression (dsRed) in relation to the trans-splicing reporter (acGFP), whereas RTMs with 
low trans-splicing efficiencies show a high amount of cells expressing exclusively the 
transfection control and less cells expressing the trans-splicing product (i.e. acGFP) as well. 
4.1 RTM library construction for plectin and screening for highly functional molecules 
For plectin we cloned two 5’ trans-splicing libraries. Trans-splicing of the RTM to the target 
results in the restoration of the open reading frame of acGFP, leading to the expression of 
the full-length protein in RTM and target co-transfected cells. Based on the previously 
described correction of PLEC by 5’ trans-splicing (Wally et al., 2008) we selected the target 
region exon/intron 9 (199bp in length) of PLEC, using the acGFP split reporter and dsRed as 
reporter for RTM transfection.  
 
 
Fig. 2. Schematic depiction of the fluorescence based RTM screening system for the plectin 
gene. 
To widen the spectrum of mutations included in the upstream coding region of PLEC, we 
constructed another library and its respective target molecule for exon/intron 30 (998bp in 
length) in parallel.  
The RTM backbone for the exon/intron 30 specific BD library includes the more intense 
tdTomato instead of dsRed as RTM transfection control. The RTM screening system requires 
cells expressing an RTM and a plectin specific target molecule. Interaction between the RTM 
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and target pre-mRNAs by RNA trans-splicing leads to the fusion of both split parts of 
acGFP, thus restoring the full-length coding sequence and expression of acGFP. The target 
molecule harbors the 3’ acGFP part flanked by a 3’ splice site (SS) and the genomic region of 
PLEC (exon/intron 9 or 30). The RTM contains the 5’ portion of acGFP linked in frame with 
the reporter gene tdTomato (for exon/intron 30) or dsRed (exon/intron 9) respectively. The 
5’ acGFP part is flanked by a functional 5’SS, a short spacer sequence and a binding domain 
randomly created by fragmenting the PLEC target region (Figure 2). 
 
 
Fig. 3. Composition of the binding domains of all RTMs tested for exon/intron 9 (A) and 
exon/intron 30 (B).  
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The 5’ trans-splicing arm of the RTM backbone, downstream of the 5’ portion of acGFP, 
contains a donor (5’) splice site, a short spacer region and a random binding domain created 
by fragmentation of the respective PLEC target region. A high diversity of RTMs with 
different binding properties to the targeted exon/intron regions was constructed either by 
sonication (exon/intron 30) or CviJI* digestion (exon/intron 9) of the PCR amplified target 
region. CviJI* produces blunt end DNA fragments, cleaving between a G and a C of the 
sequence 5’-PuGCPy-3’. The randomized CviJI* digested, as well as the blunt end repaired 
sonicated fragments were cloned into the RTM backbone. To show the robustness of the 
screening system, 5’ BD libraries consisting of about 102 to 104 individual clones were 
constructed and several randomly picked clones were sequenced to select those with the 
correct (complementary) orientation. 10 RTMs from the exon/intron 9 library (Figure 3A) 
and 22 RTMs from the exon/intron 30 library (Figure 3B) harboring one or more parallel 
and/or complementary binding domains were tested for their trans-splicing efficiency, 
quantifying GFP expression by semi-quantitative real time PCR (SQRT-PCR) on mRNA 
level (for exon/intron 30 specific RTMs) and by flow cytometry on protein level 
(exon/intron 9 and 30 specific RTMs).  
For all RTMs (1-10 for ex/in9 and 1-22 for ex/in 30) the binding domains were characterized 
and mapped (Figure 3). BDs in a complementary orientation (white bars) as well as BDs in a 
parallel orientation (black bars) were identified. Some RTMs had more than one BD 
included. BDs were named a to j and a to v respectively. Numbers next to the alphabetic 
characters indicate their order from 5’ to 3’. 
4.1.1 Screening for efficient 5’ RTMs targeting exon/intron 9 of the plectin gene 
Ten individual RTMs from a 5’ BD library were selected to show the potential and 
robustness of the RTM screening system. Eight RTMs contain complementary BDs to the 
target region exon/intron 9, inducing the trans-splicing reaction between target and RTM 
pre-mRNAs. RTMs 7 and 8 harbor a BD parallel to the target region and are therefore 
included as negative controls in the experiments. Co-transfection of target expression 
plasmids along with either one of the ten RTMs resulted in a diverse expression profile of 
dsRed and acGFP (Figure 4). Weak RTMs (1, 7-10) show only low expression levels of 
dsRED - acGFP protein in comparison to the highly efficient RTMs 2-6. RTMs 7 and 8, 
harboring parallel BDs, produce a background expression of acGFP in less than 1% of all 
analyzed cells. The most efficient RTMs 2-6 show functional acGFP expression in 44-67% of 
all treated cells with a geometric mean of acGFP expression ranging from 6 (RTM 3) to 8 
(RTM 6) (Figure 4B). These values reflect the average acGFP expression of all analyzed GFP 
positive cells. Geometric mean calculations after flow cytometric analysis were performed 
using the FlowJo software (Treestar). Flow cytometric analysis of RTM 6, 7 and 9 transfected 
HEK293AD cells show a significant difference in the amount of acGFP expression and 
fluorescence intensity (Figure 4A). RTM 6 contains a complementary BD, binding exon 9 
only, but close to the exon/intron junction, maybe influencing the 5’ splice site on the target 
molecule. This might be the reason why RTM 6 is significantly more efficient in comparison 
to RTM 7 or RTM 9, harboring a parallel (RTM 7) or a short antisense BD (RTM 9). No 
acGFP expression was detected in HEK293AD cells transfected with either target or RTM 
alone. As the binding position of RTMs 2-6 on the target molecule is similar, there was not 
much difference in reporter gene expression. Masking almost the whole exon 9 with 
complementary BDs seems to increase the trans-splicing efficiency significantly. RTMs 1, 9 
and 10 contain either short BDs specific for a short stretch of the target exon (RTM 10) or for 
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a short portion containing the 5’ exon/intron boundary (RTM 1 and 9). These RTMs induced 
acGFP expression in less than 14% of transfected cells. Additionally, the intensity of acGFP 
expression was much lower (Figure 4).  
 
 
Fig. 4. Exon/intron 9: Expression of the fluorescence reporter genes acGFP and dsRed and 
the percentage of acGFP positive cells.  
4.1.2 Screening for efficient 5’ RTMs targeting exon / intron 30 of the plectin gene 
The same experiments as described for exon/intron 9 were conducted for exon/intron 30. 
This intron was chosen to cover a maximum 5’ PLEC gene portion and thereby including 
more known mutations. Again, flow cytometric analysis was performed with HEK293AD 
cells co-transfected with RTM and target plasmids. For each RTM two independent co-
transfections were performed. Two days after co-transfection, the subset of acGFP 
expressing cells and the expression level of acGFP was quantified by flow cytometry. The 
number of acGFP positive cells and the relative amount of acGFP expressed reflect the 
functionality of RTMs and their respective binding domains. Between 5.103-2.104 
HEK293AD cells were analyzed for each transfection.  
After transfecting each of the 22 RTMs, harboring at least one complementary binding domain, 
together with the target molecule into HEK293AD cells, flow cytometry was performed. The 
geometric mean of acGFP expression ranged from 1.3 to 3.2 according to the RTM introduced 
into the target cells. The highly efficient RTMs 12, 13 and 17 showed acGFP expression in over 
20% of all transfected cells and had a calculated geometric mean of over 2.6. RTMs with a 
weak trans-splicing efficiency (e.g. RTMs 1, 4, 11) showed a high amount of cells expressing the 
RTM transfection control gene tdTomato only and less cells expressing acGFP as well (Figure 
5B). By setting the highly efficient RTMs 5, 12 and 17 in relation to the weak RTM 22, 
significant differences in their reporter gene expression were observed (Figure 5A). RTMs 5, 12 
and 17 produced significantly higher levels of acGFP. RTM 22 generated only a background 
expression of acGFP in about 1% of analyzed HEK293AD cells. 
Besides flow cytometry, all 22 RTMs with BDs ranging from 57 to 355 nucleotides, 
complementary to essentially all regions of the exon 30/intron 30 target (Figure 3B), were 
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individually tested for trans-splicing induced restoration of acGFP expression by SQRT-
PCR. A PLEC specific 5’ trans-splicing RTM is able to recombine with a target pre-mRNA by 
a specific 5’ trans-splicing reaction. Thus the exon on the target molecule is replaced by the 
5’ part of acGFP, leading to the expression of the reporter molecule acGFP in RTM treated 
cells. Trans-splicing between the RTM and target molecule was detected by semi-
quantitative real-time PCR (SQRT-PCR). For that, an acGFP specific primer pair was used to 
quantify the amount of full-length acGFP transcripts present in HEK293AD cells co-
transfected with the target molecule plasmid harboring exon/intron 30 of PLEC along with 
either one of the 22 RTMs (Figure 6). This demonstrates that the acceptor (3’) and donor (5’) 
splice sites on the target molecule and the RTM were recognized by the endogenous splicing 
machinery and that both acGFP parts were connected by 5’ RNA trans-splicing, leading to 
full-length acGFP expression. By analyzing the amount of expressed acGFP transcripts in co-
transfected HEK293AD cells, the influence of different RTM binding domains on trans-
splicing efficiency can be shown on mRNA level. As a reference gene, GAPDH was used. 
For the evaluation of the results all RTMs were referred to the weakest RTM 11 (set to 1), 
producing a low level of acGFP. As shown in Figure 6, RTMs 5, 12 and 17, accomplishing 
the exon/intron boundary of the target molecule by their complementary BDs, showed a 
high trans-splicing efficiency. RTM 12 achieved an up to 90 fold expression of acGFP 
transcripts in comparison to RTM 11. Masking the 5’ splice site on the target molecule may 
direct the ratio of the splicing reactions from cis to trans, since the binding of splicing factors 
might be disturbed. 
 
 
 
 
 
 
Fig. 5. Exon/intron 30: Expression of the fluorescence reporters acGFP : tdTomato was 
analyzed using flow cytometry (A) Four RTMs with different BDs show varying ratios of 
acGFP : tdTomato (B) The percentage of acGFP positive cells is summarized for all RTMs 
tested.   
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The data created by flow cytometric analysis (Figure 5) correlates with those obtained from 
semi-quantitative real-time PCR (SQRT-PCR). RTMs 5, 12 and 17, hybridizing to the 
exon/intron junction of the target molecule showed high trans-splicing efficiencies on 
mRNA (SQRT-PCR) and protein (flow cytometry) level, indicating the reliability of the RTM 
screening system. Since the highly efficient RTMs 5, 12 and 17 have similar complementary 
binding domains (exon/intron junction of the target molecule), this region seems to be the 
ideal binding position for efficient RNA trans-splicing in the case of the PLEC gene region 
exon/intron 30. The blockage of the exon/intron boundary of the target molecule, 
accomplished by these RTMs, may interfere with recognition of the exon 30 5’ splice site and 
facilitate trans-splicing. 
 
 
 
 
 
Fig. 6. Exon/intron 30: acGFP expression on mRNA level. 
4.2 Trans-splicing with endogenous PLEC transcripts 
One day after transfection of single RTMs into HEK293AD cells, endogenous trans-splicing 
was detected by RT-PCR. Specific trans-splicing between the RTM and the endogenous 
target pre-mRNA of PLEC resulted in the fusion of the 5’ portion of acGFP to exon 10 or 31 
of PLEC. The fusion mRNA was amplified by including an acGFP specific forward primer 
and an exon 10 or 31 specific reverse primer into the polymerase chain reaction. After gel 
electrophoresis the 5’acGFP-exon 10/31 PLEC fusion PCR product was visible on an agarose 
gel at a size of 413bp and 542bp respectively (Figure 7). The DNA band was gel purified and 
sequenced. All RTMs introduced into HEK293AD cells (RTMs specific for exon/intron 9: 1-
6, RTMs specific for exon/intron 30: 7, 12, 13), induced endogenous 5’ trans-splicing.  
www.intechopen.com
 
Human Genetic Diseases 
 
234 
 
 
 
 
 
 
Fig. 7. Single transfection of selected RTMs (exon/intron 9 or 30 RTM screen) into 
HEK293AD cells resulted in the fusion of the 5’ portion of acGFP of the RTM to the 
respective endogenous target exon of PLEC (exon 10 or exon 31) on pre-mRNA level.  
5. Discussion 
During the last years it was shown that SMaRT is a functional tool for the correction of 
disease causing mutations of many genes on mRNA level. Several approaches in different 
settings (i.e. reporter gene based, endogenous trans-splicing, in vivo application) have 
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corroborated this assumption (Dallinger et al., 2003; Coady and Lorson, 2010; Wally et al., 
2010). Also the applicability of SMaRT beyond mRNA repair was shown, using it for in vivo 
imaging and antibody and protein production. For the latter, therapeutic protein encoding 
sequences were trans-spliced to the highly abundant albumin mRNA, resulting in the 
expression of the therapeutic molecule (Wang et al., 2009). For epidermolysis bullosa, 
SMaRT was applied for a number of underlying genes, including PLEC (Wally et al., 2008), 
COL7A1 (Murauer et al., 2010), K14 (Wally et al., 2010) and COL17A1 (our unpublished 
results). Whereas for PLEC and COL7A1 the binding domains of the RNA–trans-splicing 
molecules (RTMs) were designed empirically, based on preliminary data, the binding 
domains for K14 and COL17A1 resulted from the evaluation of a number of randomly 
cloned BDs. Using a fluorescence based screening system, we saw that binding domains are 
crucial for the efficiency and specificity of the trans-splicing process. In this reporter-based 
assay, BDs were tested independently from the influence of gene characteristics and 
variations in splicing domains. This facilitated a direct comparison of the BDs, revealing a 
high impact of (a) localization within the targeted exon/intron, (b) composition and (c) 
length. Comparing obtained data, hints on principles for BD design were extracted. These 
are: (a) highly functional BDs have a length between 90 and 170bp, (b) masking of the 
competitive exon/intron junction is mostly beneficial, (c) targeting of a large intron results 
in more potential and diverse trans-splicing results since more binding sites are available. 
Furthermore, these facts underlay a hierarchy, with length ranging before splice site 
masking. Best BDs identified in the exon/intron 30 screen had a length of around 140 - 
170bp AND masked the respective target splice site. An optimal target intron is not always 
available, restricting optimization in this aspect. However, screening for BDs also revealed 
exceptions from the rule. For example binding domains from RTMs 5 and 6 for exon/intron 
9 exclusively bind within the exon. Even though we know that also splicing domains and 
spacer sequences influence trans-splicing success, regarding the BDs, it is not yet clearly 
understood what further influences trans-splicing efficiency and specificity. The first 
published BD for PLEC (Wally et al., 2008) masked the target splice site to be used for trans-
splicing, resulting in reasonable trans-splicing rates. However, we still recommend using the 
fluorescence based screening system, as this is rather facile as soon as vector backbones are 
cloned. Backbones can be used for any gene of interest and any targeted intron. Within the 
K14 gene, the applicability of SMaRT for dominant diseases was shown. The concomitant 
knock-down of the mutated and the increase of the wildtype allele multiply the effect of 
correction. Even though endogenous efficiencies are not high level, trans-splicing rates can 
be enough to revert a disease phenotype. Werner et al. showed in an in vitro model that 
dominance is limited and depends on the ratio of wildtype versus mutated K14 molecules 
(Werner et al., 2004). Also, for dominant COL7A1 mutations, overexpression of the wildtype 
protein can rescue the RDEB phenotype (Fritsch et al., 2009). Finally, Cao et al. showed that 
dominance is dependent on a certain ratio of wildtype to mutant alleles; in their in vivo 
mouse model a neomycin-resistance gene inserted in intron 1 of K14 led to a 50% reduction 
of the mutated K14 expression, resulting in phenotypically normal pups which showed no 
blistering (Cao et al., 2001). In view of this ameliorative effect, therapeutic approaches able 
to reduce the expression of a mutant gene product by 50% could be sufficient. Functional 
assays with RTM treated patient cells showed a transition of migratory behaviour and 
invasiveness versus wildtype in respective tests. 
An improvement of the screen will be the sorting of analysed cells, resulting in a faster and 
more restricted identification of highly functional RTMs. Isolation of cells showing a certain 
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ratio of the two fluorescence reporters expressed will increase the number of potential 
binding domains characterized. Single cell expansion and plasmid extraction will provide 
highly potential BDs to integrate into an endogenous setting of spliceosome mediated RNA 
trans-splicing.  
The development of an RTM selection system has a high impact on trans-splicing efficiency 
and specificity. Further improvements can be made regarding codon usage, nuclear 
retention signals, promoter selection and mode of delivery. Inclusion of nuclear retention 
signals might have great influence on the trans-splicing efficiency, but also regarding 
minimization of side effects and background expression of unspliced RTMs. Codon 
optimization and the use of weaker promoters and enhancers can be used to increase the 
safety of retrovirally introduced RTMs (Baum and Schambach, 2011; Fath et al., 2011).  
Currently, a limiting fact is the lack of mouse models meeting the exigencies of a SMaRT 
approach. Many mouse models are generated by the inclusion of intron-free genes, making 
them unfeasible trans-splicing experiments. However, mouse models are becoming easier 
available and creatable. This will pave the way to in vivo studies as the basis for clinical 
trials. 
6. Prospects and visions 
Bringing spliceosome mediated RNA trans-splicing toward clinics is the aim of presumably 
all conducted studies for mRNA correction. This technology also gives hope to patients 
suffering from EB subtypes which cannot be treated by commonly used approaches like full-
length cDNA based therapy. Patients regarding this have alterations in very large genes like 
PLEC, COL7A1 and COL17A1, and also those harbouring mutations in dominantly inherited 
genes, like K14 and K5. The next step will be to show in vivo, that trans-splicing can convert a 
disease phenotype to wildtype. The generation of viable, intron-posessing mouse models is 
a task that is being gone about currently. Looking further, ex vivo gene therapy is the 
currently most favoured approach for epidermolysis bullosa patients. Transplantation of 
skin sheets derived from autologous epidermal stem cells that were transduced with a 
respective corrective molecule is the current state of the art. This approach was successfully 
conducted for full-length cDNA therapy in junctional epidermolysis bullosa in 2006 
(Mavilio et al., 2006). There, a 50cm2 area was replaced on the patient legs. Even five years 
after transplantation the transplanted areas have not shown any blisters at all and are 
indistinguishable from healthy skin (De Luca, personal communication).  
However, systemic application of SMaRT is the technology to go for, which is not 
available yet. Delivery of (any) gene therapeutic advice is a problem common to all 
approaches. Increasing the safety of lenti- and retroviral vectors is being pushed forward 
with good results. Also the use of transposons like sleeping beauty (Hackett et al., 2010) 
and piggyBack (Yusa et al., 2011) are promising tools. Finally, targeting is another 
challenge to be overcome. However, in this case SMaRT has the advantage of being 
functional only in cells expressing the target gene, therefore minimizing off-target effects 
in other cell types.  
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